Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.830
+0.150 (5.60%)
At close: Aug 4, 2025, 4:00 PM
2.810
-0.020 (-0.71%)
Pre-market: Aug 5, 2025, 4:19 AM EDT
Perficient Employees
Iovance Biotherapeutics had 838 employees as of December 31, 2024. The number of employees increased by 281 or 50.45% compared to the previous year.
Employees
838
Change (1Y)
281
Growth (1Y)
50.45%
Revenue / Employee
$253,794
Profits / Employee
-$447,928
Market Cap
945.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | 241 | 93 | 62.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IOVA News
- 12 days ago - Here's why Iova stock surged 32% today and why the rally might not be over - Invezz
- 17 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha
- 20 days ago - Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewsWire
- 21 days ago - IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV - PRNewsWire
- 21 days ago - Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma - GlobeNewsWire
- 24 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - GlobeNewsWire
- 25 days ago - Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. - GlobeNewsWire